Optical Monobody Library Technology for Generating and Screening Light-Controlled Molecular Binding Proteins

Background

The field of molecular recognition and affinity reagents is foundational to biotechnology, medicine, and research, relying heavily on engineered proteins such as antibodies and alternative scaffolds to selectively bind target molecules. These binding proteins are essential for applications ranging from therapeutic drug purification and diagnostics to biosensing and cellular regulation. However, there is a growing demand for reagents that offer not only high specificity and affinity but also dynamic, reversible control over binding events. In particular, the ability to modulate molecular interactions with precise temporal and spatial resolution—such as through the use of light—would enable new experimental and industrial capabilities, including gentle protein purification, real-time regulation of biological pathways, and the development of smart, responsive materials.

Despite significant advances in protein engineering, current approaches to generating binding proteins face several limitations. Traditional antibodies and most engineered scaffolds exhibit static binding properties, lacking mechanisms for reversible or externally controlled interaction with their targets. Methods for introducing dynamic control, such as chemical or temperature triggers, often lack specificity, can be harsh on sensitive biomolecules, or are difficult to implement in complex biological or industrial settings. Furthermore, existing library generation techniques for alternative scaffolds are typically constrained in diversity and do not systematically enable the integration of light-responsive domains, limiting the ability to screen for binders with switchable, light-dependent properties. As a result, researchers and industry practitioners are often forced to compromise between binding performance and controllability, hindering the development of next-generation affinity reagents for advanced applications.

Technology

This technology enables the creation of vast libraries of optical monobodies—engineered protein scaffolds that exhibit reversible, light-dependent binding to a wide array of molecular targets. By fusing the light-sensitive AsLOV2 domain from Avena sativa into a monobody scaffold derived from the 10th fibronectin type III domain (FN3), these chimeric proteins can bind targets in darkness and release them upon exposure to blue light. The system utilizes two primary scaffolds, OptoMB and Moonbody, which differ in their AsLOV2 insertion points and binding interfaces, thereby broadening the range of potential target interactions. Library diversity, reaching up to 10^15 unique variants, is achieved by introducing degenerate sequences into three variable regions flanking the AsLOV2 domain. Three validated PCR-based methods—Two Tandem PCR/Ligations, Overlap Extension PCR, and Single PCR and Ligation—allow for efficient construction of these libraries, which are then screened using high-throughput techniques like ribosome display to isolate monobodies with precise, light-switchable binding properties.

This technology is differentiated by its unprecedented combination of temporal and spatial control, high affinity, and broad applicability. Unlike traditional antibodies or binding proteins, optical monobodies can be reversibly switched between binding and non-binding states using light, enabling precise regulation of molecular interactions without harsh chemical treatments. The dual-scaffold architecture (OptoMB and Moonbody) provides complementary binding surfaces, increasing the likelihood of isolating effective binders for diverse targets. The ability to generate libraries with up to 10^15 variants ensures comprehensive coverage of potential binding sequences, while the modular PCR-based diversification strategies offer flexibility and scalability. Applications span from light-controlled affinity chromatography for gentle protein purification, to in vivo regulation of biological processes, to the development of smart materials and biosensors. The technology’s versatility, ease of implementation, and capacity for high-throughput, light-dependent selection set it apart from conventional molecular recognition tools, making it highly attractive for research, industrial, and therapeutic uses.

Benefits

• Enables reversible, light-controlled binding and release of molecular targets, allowing precise temporal and spatial regulation of interactions.
• Generates extremely large and diverse libraries (1010–1015 variants) for isolating high-affinity, light-switchable binders against a broad range of targets.
• Offers gentle, non-chemical elution methods for protein purification, preserving protein integrity and functionality.
• Supports multiple validated molecular biology methods for flexible and efficient library construction and diversification.
• Compatible with various high-throughput screening platforms to rapidly identify effective optical monobodies.
• Applicable across diverse fields including biopharmaceutical manufacturing, diagnostics, biological research, therapeutics, and smart materials.
• Provides antibody-like binding affinities with the added advantage of reversible and controllable binding via light stimulation.

Applications

• Light-controlled protein purification
• Optogenetic regulation of cellular processes
• Light-activated therapeutic agents
• Light-switchable biosensors
• Smart light-responsive biomaterials

Additional info

Methods generate vast libraries of engineered protein scaffolds, termed optical monobodies. These chimeric proteins integrate a light-sensitive domain with a binding domain, enabling reversible, light-dependent molecular recognition. Library diversity (10^10-10^15 variants) is achieved via PCR-based diversification of variable regions. High-throughput screening isolates specific binders that engage targets in darkness and release them upon blue light exposure.